Dimension Capital Management Partners purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 14,602 shares of the biopharmaceutical company’s stock, valued at approximately $1,034,000.

A number of other hedge funds and other institutional investors have also modified their holdings of GILD. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in shares of Gilead Sciences by 583.3% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 1,400 shares during the period. Penserra Capital Management LLC lifted its holdings in shares of Gilead Sciences by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares during the period. American Beacon Advisors Inc. acquired a new stake in shares of Gilead Sciences during the first quarter worth about $143,000. Washington Trust Bank lifted its holdings in shares of Gilead Sciences by 24.8% during the second quarter. Washington Trust Bank now owns 2,767 shares of the biopharmaceutical company’s stock worth $196,000 after purchasing an additional 550 shares during the period. Finally, Adalta Capital Management LLC acquired a new stake in shares of Gilead Sciences during the first quarter worth about $204,000. 74.38% of the stock is owned by institutional investors and hedge funds.

A number of research firms recently commented on GILD. BidaskClub downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Mizuho lifted their target price on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday. Deutsche Bank AG reaffirmed a “buy” rating and set a $81.00 target price (up previously from $79.00) on shares of Gilead Sciences in a report on Thursday, July 27th. Leerink Swann reaffirmed a “hold” rating and set a $74.00 target price on shares of Gilead Sciences in a report on Tuesday, July 25th. Finally, Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Thursday, October 19th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $85.92.

Gilead Sciences, Inc. (GILD) opened at $73.77 on Friday. The firm has a market capitalization of $95,383.76, a price-to-earnings ratio of 7.62, a price-to-earnings-growth ratio of -1.22 and a beta of 1.13. The company has a debt-to-equity ratio of 1.10, a quick ratio of 4.74 and a current ratio of 3.68. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. During the same quarter in the previous year, the company posted $2.75 earnings per share. The firm’s revenue for the quarter was down 13.2% compared to the same quarter last year. equities analysts forecast that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be paid a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.82%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 23.69%.

ILLEGAL ACTIVITY WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/dimension-capital-management-partners-invests-1-03-million-in-gilead-sciences-inc-gild-stock/1694864.html.

In other news, EVP Gregg H. Alton sold 50,000 shares of the company’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $79.00, for a total value of $3,950,000.00. Following the transaction, the executive vice president now owns 113,237 shares of the company’s stock, valued at approximately $8,945,723. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP James R. Meyers sold 60,000 shares of the company’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $83.19, for a total value of $4,991,400.00. Following the completion of the transaction, the executive vice president now directly owns 62,715 shares in the company, valued at approximately $5,217,260.85. The disclosure for this sale can be found here. In the last ninety days, insiders sold 446,819 shares of company stock worth $36,269,486. Corporate insiders own 1.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.